TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02201667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180-mg loading dose followed by 90mg twice daily for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 300-mg loading dose followed by 75mg once daily for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 300mg loading dose aspirin and followed by 100mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 300mg loading dose aspirin and followed by 100mg once daily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
Study: NCT00714337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: One single oral dose of 90mg (3 x 30mg AZD1386 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: One single oral dose of 90mg (3 x 30mg AZD1386 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: One single oral dose of 90mg (6 x 15mg AZD1386 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: One single oral dose of 90mg (6 x 15mg AZD1386 tablets)
Study: NCT02452749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardiovascular health dietary supplement
Description: Herbal/mineral dietary supplement
Study: NCT02152449

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation
Study: NCT02324868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shower patch IV catheter protection
Description: Shower patch will be available for the patient for bathing activities

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional IV catheter protection
Description: No Shower patch will be provided during study period
Study: NCT04675697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-etoposide+Anlotinib
Description: Platinum-etoposide regiment consisted of etoposide 100mg/m2, d1\~3 of 21-day cycle, with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5\~6, Q3W). Anlotinib treated of 12mg Qd from day 1 to 14 of a 21-day cycle. Eligible patients received anlotinib plus platinum-etoposide for 4\~6 cycles, and followed by maintenance therapy with Anlotinib. The efficacy was evaluated every 6 weeks (2 cycles) through treatment.
Study: NCT02189304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT010
Description: PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PT010
Description: PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT009
Description: PT009 administered as 2 inhalations
Study: NCT00915759

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bandage contact lens
Description: Bandage contact lens placed in dominant eye, the current standard after PRK
Study: NCT04769271

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing
Description: Supra- and sub-gingival calculus and debris were removed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing with tea tree oil
Description: Supra- and sub-gingival calculus and debris were removed and 5% tea tree oil was applied
Study: NCT01765036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue®
Description: An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
Study: NCT04329728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVM0703
Description: Intravenous infusion over \~1 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVM0703
Description: Intravenous infusion over \~1 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVM0703
Description: Intravenous infusion over \~1 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVM0703
Description: Intravenous infusion over \~1 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVM0703
Description: Intravenous infusion over \~1 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVM0703
Description: Intravenous infusion over \~1 hours
Study: NCT01225133

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex Ayurvedic Treatment
Description: In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex Ayurvedic Treatment
Description: In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
Study: NCT01604525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Web
Description: The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Web
Description: The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coaching
Description: Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Untailored Web
Description: Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
Study: NCT03335904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxic Hypercapnic Ventilatory Response Test
Description: End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyperoxic Hypercapnic Ventilatory Response Test
Description: End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic Hypercapnic Ventilatory Response Test
Description: End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxic Hypercapnic Ventilatory Response Test
Description: End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated Hypoxic Apneas
Description: Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Repeated Hypoxic Apneas
Description: Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic Sleep Study
Description: Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxic Sleep Study
Description: Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan, 50mg, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 50mg, BID
Study: NCT04031248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: In this study an axial vibratory platform will be used: POWER-PLATE pro 5 AIRdaptive TM HP®. This device is reviewed annually by the technical unit of the company itself and complies with the international regulations that regulate the Medical Devices \[Devices Directive (MDD) 93/42 / EEC (ISO 2631. 2011, Powerplate.com, 2013)\]. The vibration will be administered with 2 mm of amplitude and 40 Hz of frequency.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EXERCISE group
Description: The program will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work. The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience.
Study: NCT02466425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465
Description: 12.5mg and 25mg capsules (one capsule daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule that appear identical in size, weight, shape, color
Study: NCT00470262

Intervention type: DRUG
Group type: OTHER
Intervention: Fenofibrate 145mg PO QD
Description: Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone

Intervention type: DRUG
Group type: OTHER
Intervention: Fenofibrate 145mg PO QD
Description: Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone

Intervention type: DRUG
Group type: OTHER
Intervention: Pioglitazone 45 mg PO QD
Description: Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
Study: NCT01760499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PV-10
Description: PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
Study: NCT02189304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PT009
Description: PT009 administered as 2 inhalations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler
Description: Symbicort Turbohaler taken as 2 inhalations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler
Description: Symbicort Turbohaler taken as 2 inhalations
Study: NCT03174561

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Inuline, Choline and Silymarin
Description: Combination of one sachet: Inuline (5000 mg), Silybum marianum seed extract (50 mg), Choline (37 mg) The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days. Diet restriction is consider together with dietary supplement intake.
Study: NCT03638674

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DXA + CT
Description: Two dual-energy X-ray scans + CT scan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DXA + CT
Description: Two dual-energy X-ray scans + CT scan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DXA + CT
Description: Two dual-energy X-ray scans + CT scan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DXA + CT
Description: Two dual-energy X-ray scans + CT scan
Study: NCT05088434

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anaerobically Cultivated Human Intestinal Microbiota (ACHIM)
Description: One vial of ACHIM suspension (ACHIM Biotherapeutics AB, Vallingby, Sweden), containing 30 x 109 colony forming unit (CFU) of bacteria, was given through the work channel of a gastroscope into the lower part of duodenum.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Donor fecal microbiota transplantation
Description: Only 60 ml of sterile 0.9% normal saline were added to a stool specimen, collected from the respective donor, with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only 60 ml of sterile 0.9% normal saline were added to the patient's own stool specimen with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
Study: NCT01518725

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
Study: NCT04383028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MELD algorithm use to aid in the planning of SEEG electrode trajectories
Description: During the routine SEEG planning meetings, the planning of SEEG trajectories, including the number and location of electrodes, will follow the usual clinical pathway and be planned according to the expertise of the attending neurosurgeon, neurophysiologist and neurologist at the multidisciplinary team meeting. Once the trajectories have been planned, anonymised scans for each patient (linked to them via a unique study ID) will be run through the MELD classifier and the top 3 MELD identified lesion clusters will be considered for further implantation.~These top 3 MELD classifier identified clusters will then be merged with the existing clinical plan to assess if each of the clusters are already being sampled by an SEEG electrode. If there is already an electrode in each lesion, no adjustments will be made. If there are clusters that are not being recorded from, and it is technically possible, extra electrodes (up to 3) will be added to record from these additional locations.
Study: NCT03147378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
Study: NCT00810771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Information
Description: A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Information
Description: A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preference-tailored Information
Description: A preference elicitation exercise that will generate a list of the three top attributes for the subject and the CRC screening test most consistent with these attributes. Subjects will be provided with a handout to take to their clinic appointment as the Standard Information group does, but with the addition of a listing of their top attributes and the test most consistent with their top attributes.
Study: NCT04492748

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Collagen and platelet rich plasma (PRP)
Description: Ultrasound guided injections

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen
Description: Ultrasound guided injections

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma (PRP)
Description: Ultrasound guided injections
Study: NCT00848835

Intervention type: DEVICE
Intervention: defibrillation lead (ENDOTAK EZ and RELIANCE)
Description: defibrillation lead
Study: NCT02827760

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synergy1
Description: Inulin type fructans

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT02808325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelaspan 4%
Description: Gelaspan 4% combined with Sterofundin ISO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelofusine 4%
Description: Gelofusine 4% combined with Sodium Chloride
Study: NCT02110186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Stabilization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Instrumentation and fusion
Study: NCT02303210

Intervention type: DEVICE
Group type: OTHER
Intervention: hearing aid NaidaUP
Description: Standard Power Hearing instruments including different frequency lowering techniques

Intervention type: DEVICE
Group type: OTHER
Intervention: hearing aid NaidaSP
Description: Standard Power Hearing instruments including different frequency lowering techniques
Study: NCT00750035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy
Description: Total abdominal hysterectomy and Subtotal abdominal hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtotal abdominal hysterectomy
Study: NCT04413214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrimycin
Description: The study involves three dose groups: 200mg, 400mg and 600mg. Three patients are planned for each dose group. Starting from the low dose group, the treatment to three patients in the 200mg dose group: 200mg of Carrimycin after meals every morning (po) for three weeks, and then discontinue for one week, the tolerance and efficacy evaluation will be performed after the 4 weeks. DLT will be recorded during the 4 weeks.
Study: NCT03260855

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires/Scales
Description: Scale of Fear of Cancer Recurrence Inventory, Hospital Anxiety and Depression Scale, Evaluation of stress and life quality.

Intervention type: OTHER
Group type: OTHER
Intervention: Human blood sample
Description: The intervention is based on blood test.